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 Perivascular adipose tissue (PVAT) is a type of fatty tissue that surrounds and interacts 
with blood vessels, consisting of both brown and white adipose tissue depots (BAT, WAT). BAT 
is responsible for thermoregulation and energy expenditure while WAT stores energy in the form 
of triglycerides. Excessive accumulation of WAT has been correlated with obesity – a 
comorbidity for cardiovascular disease (CVD). Also, WAT adipocytes release inflammatory 
adipokines which cause inter-arterial inflammation in the form of atherosclerotic depots leading 
to CVD. The goal of the study was to assess the expansion of WAT and BAT in aortal PVAT 
isolated from rats with and without heart failure in the presence and absence of β-adrenergic 
stimulation (isoproterenol). Heart failure was induced via transverse aortic constriction (TAC). 
PVAT was harvested from SHAM and TAC rats and placed in Matrigel with growth media with 
and without isoproterenol. After 7 days, WAT from TAC rats grew more compared to SHAM 
(783±129 vs 519±202 mm3; n=4). Conversely, BAT from SHAM rats expanded more compared 
to TAC (755±187 vs 523±61 mm3; n=4). In the presence of isoproterenol, angiogenesis 
decreases in BAT and WAT from both SHAM (from 755±187 to 5±5 and from 519±202 to 
370±224 mm3, n=4,2) and TAC (from 523±61 to 29 and from 783±129 to 86 mm3, n=4,1) rats, 
demonstrating β-adrenergic stimulation blunted the expansion of WAT from TAC rats (89% 
decrease) more than SHAM rats (29% decrease). These results may form potential therapies for 
obesity in individuals with heart failure. Further investigation may include additional 
interventions in order to provide a greater biological understanding of PVAT expansion. 
Introduction 
 Obesity, a disease characterized by a significant gain in unhealthy fat mass, currently 
affects over 475 million individuals and kills over 2 million worldwide annually (Withers et al., 
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2014). Data indicates the prevalence of adiposity has steadily increased in the past few decades, 
currently impacting over 40% of American adults and 20% of youth in the United States (Ogden, 
Carroll, Fryar, & Flegal, 2015). The cost of obesity, and obesity related issues, is estimated to be 
between 147 and 210 billion dollars annually for the U.S. - 20% of the total medical spending in 
the country (Moore, Amey, & Mpofu, 2018). Since these numbers have been rising, obesity has 
been deemed a public health emergency with severe financial and economic consequences 
(Pellegrinelli, Carobbio, & Vidal-Puig, 2016). At its core, obesity is an accumulation of fat mass 
in the form of adipose tissue (AT), but this accumulation is only the beginning of several medical 
complications and diseases. 
 AT growth may occur in two different ways: hyperplasia and hypertrophy. Hyperplasia is 
the increase in adipocyte number allowing for healthy growth since each cell originates from a 
progenitor cell (R. Berry, Jeffery, & Rodeheffer, 2014; Fuster, Ouchi, Gokce, & Walsh, 2016). 
Hypertrophy, on the other hand, is the increase of adipocyte size which leads to large lipid filled, 
dysfunctional cells (R. Berry et al., 2014; Fuster et al., 2016). A result of hypertrophy is the 
increased secretion of pro-inflammatory signals, termed adipokines, which impact surrounding 
adipocytes as well as proximal tissues. The main adipokines linking obesity and CVD are the 
same inflammatory markers secreted from AT (Padilla, Jenkins, Vieira-Potter, & Laughlin, 
2013; Tanaka & Sata, 2018). Specifically, TNF-a, MCP-1, IL-6, and IL-1 are implicated in CVD 
and have been found in inflamed adipocytes (Padilla et al., 2013). The release of these 
inflammatory molecules leads to the continuous growth of adipocytes in the region as well as 
forcing the microenvironment to experience chronic inflammation contributing to CVD (Fuster 
et al., 2016; Pellegrinelli et al., 2016). This inflammation-induced inflammation cycle is also 
associated with insulin resistance in the vasculature, skeletal muscles, and liver (Bays, 2011; R. 
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Berry et al., 2014; Fuster et al., 2016). As a result of these metabolic perturbations, obesity is a 
co-morbidity for heart disease, type 2 diabetes, atherosclerosis, stroke, and death (Cao, 2010), 
directly linking CVD, the leading cause of death in America, to AT. 
 At the cellular and molecular level, AT is comprised of adipocytes, which are droplets of 
lipids in the form of triglycerides (Arner et al., 2011). While originally thought to only provide 
structural support and energy storage, the role of AT has expanded to include a wide breadth of 
functions. AT not only insulates the body, but also has thermoregulatory mechanisms. Even 
though AT’s main function is a large depot for energy storage, it is able to dispense the energy 
through lipolysis – a crucial process of lipid breakdown which is impaired in those affected by 
obesity (Arner et al., 2011). Besides the structural and metabolic functions, AT exhibits 
paracrine capabilities as well. Specifically, adipocytes secrete a range of adipokines (Catalan, 
Gomez-Ambrosi, Rodriguez, & Fruhbeck, 2013; Valencak, Osterrieder, & Schulz, 2017), 
indicating adipocytes interact with their microenvironment and elicit metabolic changes based on 
the signaling molecules released. This is a key function since AT directly impacts the tissue it 
borders (Horimatsu, Kim, & Weintraub, 2017; Tanaka & Sata, 2018). 
 AT is not homogeneous throughout the body and multiple types of AT have been 
phenotypically sorted and genetically confirmed. Two important types of AT found in humans 
are brown adipose tissue (BAT) and white adipose tissue (WAT). Depots of both can be found in 
visceral and subcutaneous locations but they have distinct phenotypic and functional properties 
(Arner et al., 2011; D. C. Berry, Stenesen, 
Zeve, & Graff, 2013). As the names 
suggest, there is a clear color difference 
between the two since BAT is seen as 
Figure 1: UCP-1. It can act as both a “release valve” 
and a “leak”. 
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brown and WAT is seen as white. The two different types of AT also have varied stem cell 
origins (D. C. Berry et al., 2013). BAT’s main function is to generate heat in order to aid in 
thermoregulation (D. C. Berry et al., 2013). These cells are able to exploit the higher 
mitochondria content within BAT for this purpose as the protein arrangement in the organelle 
allows for energy dissipation as a result of uncoupling protein 1 (UCP-1) (D. C. Berry et al., 
2017; D. C. Berry et al., 2013; Lowell & Flier, 1997). This system has positive and negative 
effects, which are largely context dependent, but can be viewed as either a “release valve” or a 
“leak” within the mitochondria (Fig. 1). The “release valve” is beneficial as it can alleviate the 
buildup of hydrogen ions within the inner mitochondria membrane, bypassing the ATP synthase 
complex, and utilizing the electrochemical gradient to produce heat. On the other hand, UCP-1 
can act as a leak because it dissipates the mitochondrial membrane potential lowers the 
production of usable energy in the form of ATP, rendering the mitochondria less efficient in 
terms of ATP production. WAT is responsible for energy storage in the form of triglycerides and 
lipids as well as coordinating systemic metabolism (D. C. Berry et al., 2013). The latter function 
is illustrated by metabolic dysfunctions such as hyperglycemia, hypertension, and diabetes in the 
presence of an abnormal number of white adipocytes, specifically in those suffering from obesity 
(D. C. Berry et al., 2013).  
 Past studies have found another difference between BAT and WAT: the mechanism of 
remodeling (Hattori, Yamamoto, & Matsuda, 2007; Tonello et al., 1999). It is generally agreed 
upon that BAT is healthier than WAT though both are required in a limited amount to maintain a 
healthy homeostasis. The expansion of WAT leads to lypolytic imbalance causing hormone 
dysfunction leading to a host of other problems including high blood pressure, triglycerides, and 
a higher risk of developing type 2 diabetes and CVD (Bloor & Symonds, 2014). With a capacity 
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to impact systemic metabolism and communicate with its microenvironment, 
WAT, and particularly its expansion, presents a unique opportunity for 
therapeutic interventions. 
 As dangerous as excess AT may be, its impact on the CV system 
depends on its location. Perivascular adipose tissue (PVAT) is identified by 
its crucial location, surrounding blood vessels. The largest depots of 
PVAT are located tangent to the aorta without any significant anatomical 
barrier between the two (Horimatsu et al., 2017). BAT surrounds the 
lining of the thoracic aorta above the diaphragm, while WAT is found in the abdominal cavity 
around the distal aorta (Fig. 2). Activated BAT has been shown to reduce plasma triglyceride 
levels, accelerate uptake of cholesterol-rich remnants, and eliminate atherosclerotic lesions in 
some rats (Hoeke, Kooijman, Boon, Rensen, & Berbee, 2016). Inflamed WAT becomes a local 
source of inflammatory cytokines such as TNF-a, MCP-1, IL-6, and IL-18 (Padilla et al., 2013). 
These adipokines are able to quickly diffuse into the adjacent arterial wall causing inflammation 
inside the artery in the form of atherosclerotic deposits (Tanaka & Sata, 2018). These 
atherosclerotic deposits are known to be threatening and indicators of CVD. It has also been 
noted that an increase in WAT causes circulating lipid profiles to become pro-atherogenic (van 
Dam, Boon, Berbee, Rensen, & van Harmelen, 2017). Thus, the non-uniform susceptibility to 
atherosclerosis within the arterial tree is partially attributable to regional phenotypic differences 
in PVAT. Evidence indicates PVAT can alter vascular function, however the impact of PVAT 
expansion on its associated regional locations remains elusive, despite the known deleterious 
effects of excessive AT. Accordingly, PVAT and its capacity for expansion may be a critical 
intermediate between adiposity and overt CVD.  
Figure 2. PVAT 
Regional Heterogeneity. 
BAT is located in the 
thoracic cavity. WAT is 
found in the abdominal 
region. 
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 As mentioned earlier, all AT is healthy in moderation - the issues lie in its expansion. 
Adipogenesis is the generation and expansion of new and necessary adipocytes (Hausman & 
Richardson, 2004). All adipocytes interact with the CV system, as AT is the most vascularized 
tissue (Padilla et al., 2013). Due to this connection, the process of adipogenesis is tightly coupled 
with angiogenesis. Broadly, angiogenesis is the formation of new capillaries which can occur in 
two forms: 1) the creation of new capillaries from existing capillaries or 2) the ‘sprouting’ of 
capillaries from an existing capillary and extending into the surrounding extracellular matrix 
(Diaz-Flores et al., 2017). The CV system is crucial in this process since it is able to provide the 
necessary nutrients and growth factors to foster the formation of new blood vessels (Cao, 2010). 
Though the connection between adipocytes and the CV system is critical, AT is able to take 
advantage of the relationship in a few ways. Adipocytes can secrete plasminogen activator 
inhibitor-1 and leptin, key proteins in fatty tissue, which ensure the coordination of adipogenesis 
and angiogenesis in a synergistic manner (Cao, 2010; Hausman & Richardson, 2004). AT can 
also induce the release of vascular endothelial growth factor (VEGF) in two different ways. First, 
the reconstruction of lipids causes the degradation of basal membrane proteins, a type of 
extracellular proteolysis that is linked to the release of VEGF, causing angiogenesis (Hausman & 
Richardson, 2004). Second, areas of AT undergoing hyperplasia and hypertrophy experience 
brief hypoxia, generating a large chemotactic stimuli from these new adipocytes (Gealekman et 
al., 2014). Hypoxia-induced growth factors, such as VEGF, are released, angiogenesis is 
initiated, and nutrient delivery to the new AT is established (Gealekman et al., 2014). AT’s 
ability to expand using the vasculature is a critical part of current research into unhealthy 
hypertrophy but angiogenic factors delivered by the CV system are not the only route for PVAT 
expansion. 
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 Previous literature indicates AT retain a large amount of adrenergic innervation, which 
may be partially responsible for mediating growth of adipocytes (Tonello et al., 1999). α- and β-
adrenergic receptors are a class of membrane proteins, ligands for norepinephrine and 
epinephrine, and an integral part of the sympathetic nervous system. The three β-adrenergic 
receptors are all activated during a sympathetic response, but the functions elicited are tissue 
specific. For instance, stimulation of β-1 in the heart is responsible for increasing heart rate, β-2 
stimulation in the vasculature is involved in vasodilation, and stimulation of the β-3 receptor has 
been shown to induce lipolysis (Granneman, Li, Zhu, & Lu, 2005). In particular, the β-3 
adrenergic receptor has received the most attention in light of its putative interactions regarding 
the angiogenic capacity of AT. Notably, stimulating AT with β-3 agonists has been shown to 
stunt its expansion. In general, treatment with β-3 agonists in rodents has been shown to increase 
AT-specific energy expenditure and reduce overall obesity (Lowell & Flier, 1997). At the 
molecular level, stimulation with β-3 agonists stimulates mitochondrial biogenesis by 
augmenting cAMP production, thus promoting mitotic divisions and eliciting higher respiration 
rates (Fig. 3) (Granneman et al., 2005; Lafontan & Berlan, 1993; Lowell & Flier, 1997). The 
overall result is fatty acid combustion and lipolysis and a decrease in AT at the site of 
stimulation (Fig. 3), however there have been no studies of the effect of β-3 stimulation or 
inhibition on PVAT (van Dam et al., 
2017).  
 The regional differences of 
PVAT encourages inquiry into how β-
adrenergic agonists and antagonists 
impact growth. Norepinephrine, a non-
Figure 3: Diagram of the Lipolysis Pathway due to Beta 
Agonists 
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specific adrenergic receptor agonist, induces thermogenesis in BAT resulting in a high demand 
for oxygen. More than half of the stored energy in BAT may be used during this process in order 
to sustain homeostasis (D. C. Berry et al., 2013). This adrenergic-induced process stimulates the 
release of VEGF to rebuild the lost AT (Fredriksson, Lindquist, Bronnikov, & Nedergaard, 
2000). Moreover, a correlation has been shown between the activation of adrenergic receptors 
and the increase expression of VEGF in BAT (Tonello et al., 1999). Importantly, WAT has a 
different response to adrenergic receptor agonists. White tissue is seen to remodel in a specific 
type of process termed browning (Granneman et al., 2005; Harms & Seale, 2013). Browning is 
the process that transforms WAT into brown-like tissue as seen by the presence of thermogenic 
genes (Harms & Seale, 2013). This process can occur during cold temperatures which requires a 
more significant amount of energy for thermoregulation (D. C. Berry et al., 2017). This process 
changes the AT to adapt to the microenvironment but does not consist of induced lipolysis as is 
seen in typical BAT. Besides these differences there may be other effects of β-adrenergic 
agonists and/or antagonists on PVAT. 
 As the mortality rate increases due to CVD and obesity, it is clear that there is a dire need 
to better understand the role of AT as it impacts both perivascular and AT. A better 
understanding of the role of PVAT as well as the impact of β-agonists and antagonists on AT 
expansion has the potential to translate into viable therapeutic interventions designed to 
ameliorate and prevent CVD. 
Specific Aims and Hypotheses 
 Overall, the goal of this study is to gain a better understanding of PVAT expansion and 
the regional differences in AT depots along the aorta. In order to capture the putative differences 
in AT heterogeneity, BAT from the thoracic aorta and WAT lining the abdominal aorta will be 
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examined (Fig. 2). A rat model to investigate the effect of CVD on PVAT phenotype and growth 
by incorporating healthy and heart failure rats will be utilized. The impact of β-adrenergic 
agonists on PVAT expansion will also be tested.  
SPECIFIC AIM #1: To determine the impact of perivascular adipose tissue regional and 
phenotypic heterogeneity on PVAT sprouting and growth in rats with and without heart 
failure. 
• Hypothesis 1.1: Thoracic PVAT (BAT) will have significantly more expansion compared to 
abdominal PVAT (WAT) in SHAM rats. VEGF receptor concentrations show BAT relies on 
VEGF while WAT does not. 
• Hypothesis 1.2: Thoracic PVAT (BAT) from SHAM rats will have significantly more 
expansion compared to its respective depot in TAC rats. VEGF receptors are not active in 
unhealthy rats and will not influence BAT growth to the same degree. 
• Hypothesis 1.3: Abdominal PVAT (WAT) from SHAM rats will have significantly less 
expansion compared to its respective depot in TAC rats. WAT in TAC rats will produce more 
inflammatory adipokines which will cause the PVAT to expand to a greater degree. 
SPECIFIC AIM #2: To ascertain the role of β-adrenergic agonists and antagonists on 
PVAT phenotype and expansion in rats with and without heart failure. 
• Hypothesis 2.1: β-agonists, specifically β-3, in thoracic and abdominal PVAT will decrease 
PVAT growth. β-adrenergic stimulation will activate lipolysis and reduce PVAT expansion. 
• Hypothesis 2.2: β-antagonists will cause the β-adrenergic receptors to lose their function 
resulting in an increase growth of both thoracic and abdominal PVAT. β-inhibitors will make 
it impossible to activate growth inhibition resulting in uncontrollable expansion. 
Materials and Methods 
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Animal Handling & Transaortic Constriction Surgery: 
 For the proposed studies, rats will undergo SHAM and TAC surgery. Rats undergo the 
surgery at 4 weeks under deep anesthetization. Briefly, a longitudinal cut was made in the 
sternum and a suture spaced with a 20 gauge needle was tied around their transvers aorta. 22 
weeks after SHAM or TAC surgery, the animals were sacrificed, and PVAT was excised for 
growth/expansion assay. All protocols for animal handling are approved by the Institutional 
Animal Care and Use Committee (IACUC). 
 Transverse aortic constriction (TAC) surgery is a common procedure performed to create 
a CVD model in rats. The operation implants a small ring around the aorta. This constriction 
ultimately increases blood pressure and leads to cardiac hypertrophy, a type of CVD(deAlmeida, 
van Oort, & Wehrens, 2010). Provided obesity and its related comorbidities typically manifest 
simultaneously, this model will provide experimental control to tease apart the impact of normal 
aging-related obesity and CVD. Thus, we will utilize a surgical intervention, TAC-induced heart 
failure, to determine its role in PVAT expansion. In order to reduce the number of different 
variables, we will incorporate SHAM rats that undergo a placebo surgery, as the experimental 
control. 
PVAT Growth/Expansion Assay: 
 Aortas and accompanying PVAT was extracted. Thoracic and abdominal aorta/PVAT 
was separated, placed in microvascular endothelial growth media (EGM-Mv) until PVAT is 
further dissected and separated from the aorta. Aortas are stored at -20°C for future assays. Next, 
PVAT is cut into small slices (< 1 mm3) and embedded into a 96-well plate with Matrigel. After 
PVAT embedding, the 96-well plate incubates at 37°C with 5% CO2 for 30 min. Unused PVAT 
is stored at -20°C for future assays. After incubation, 200 µL of EGM-Mv is added to each well, 
 12 
and the plate is returned to 37°C with 5% CO2 for 7 days. Images of PVAT explants were taken 
on a Zeiss microscope 1, 3, 5, and 7 days after embedding. Images were analyzed by outlining 
PVAT area on each day (Fiji, ImageJ). Growth area was calculated by subtracting the size of the 
explant from the area on days 1, 3, 5, and 7. On days 2, 4, and 6 half of the EGM-Mv media is 
replaced with fresh EGM-Mv. The removed media is stored -20°C for future assays. 
Drug Interventions: 
 β-adrenergic agonists isoproterenol was utilized. This drug, with concentrations of 1x10-
8M, was added to EGM-Mv during extraction, preparation, and media changes. 
Statistical Analysis & Power Calculations: 
 There are no existing data on which to base power calculations to determine the effect of 
heart failure, or adrenergic innervation on the regional heterogeneity of PVAT expansion as 
proposed. Thus, a priori power calculations indicate a sample size of 8 is sufficient to detect the 
effect of all variables on outcome measures estimated with an effect size f = 0.35, 1- β = 0.80, 
and α = 0.05 (analysis via G*Power). Data was analyzed using a 2 × 2 (TAC/drug/VEGF × 
PVAT depot) repeated measures-ANOVA. Fishers LSD test are used for post-hoc comparisons, 
with P < 0.05 as the criterion for statistical significance. All statistical analyses was performed in 
SPSS. 
Results 
 We began our experiments by examining BAT and WAT expansion in SHAM (n=4) and 
TAC rats (n=4). The results indicate that SHAM BAT grew more than the SHAM WAT. These 
results are consistent with our hypothesis 1.1 which relied on the impact of VEGF. The results in 
TAC rats showed that WAT had more growth than BAT (Fig. 4). This was expected provided 
CVD is linked to the presence of abnormally large WAT deposits (D. C. Berry et al., 2013; Bloor 
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& Symonds, 2014; Brinkley et 
al., 2014; Britton et al., 2012; 
Padilla et al., 2013). A 
comparison was also made 
between PVAT in healthy 
control and TAC rats. The 
thoracic BAT grew significantly more in the control rats (Fig. 4A) while the abdominal WAT 
expanded more in the TAC rats (Fig. 4B). We hypothesize that these results are due to the VEGF 
presence since BAT in obese rats is not able to use VEGF properly (Tonello et al., 1999).  
 Isoproterenol (ISO), a non-selective β-agonist, was used to induce activity in all β-
receptors within the PVAT (Granneman et al., 2005; Lafontan & Berlan, 1993). In healthy rats 
(n=2), BAT and WAT were impacted differently by the presence of ISO. BAT growth was 
stunted, while abdominal PVAT was not impacted to the same degree but was still seen to 
decrease (Fig. 5 A&B). The difference in growth may partially be explained by the distinct 
effects of β-agonists on the two AT depot: BAT uses UCP-1 to produce energy in the form of 
heat to compensate for the activation of the β-receptors while WAT does not have UCP-1 and is 
not as impacted by β-activation (D. C. Berry et al., 2017; D. C. Berry et al., 2013; Granneman et 
al., 2005; Lafontan & Berlan, 
1993; Lowell & Flier, 1997; 
van Dam et al., 2017). In TAC 
rats (n=1), BAT and WAT 
were impacted in the same 
Figure 4. Expansion of Thoracic PVAT and Abdominal PVAT in SHAM and 
TAC rats. A, Thoracic PVAT growth in SHAM (n=4) and TAC rats (n=4) over 
seven days. B, Abdominal PVAT growth in SHAM (n=4) and TAC (n=4) rats over 
seven days. 
Figure 5. Impact of Isoproterenol on Thoracic PVAT and Abdominal PVAT 
Expansion in SHAM and TAC rats.  A, Thoracic PVAT growth in SHAM (n=4), 
TAC rats (n=4), SHAM with isoproterenol (ISO) (n=2), and TAC rats with ISO (n=1) 
over seven days. B, Abdominal PVAT growth in SHAM (n=4), TAC rats (n=4), 
SHAM with ISO (n=2), and TAC rats with ISO (n=1) over seven days. 
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way by the presence of ISO. Both types of AT had less growth when incubated with ISO (Fig. 5 
A&B). These results may be attributed to the CVD and adiposity inherent to TAC rats, 
potentially causing biological processes to degrade. However, more research is needed to 
determine the impact of CVD on the function of PVAT β-receptors. 
Discussion 
 Our investigations have provided a greater understanding of PVAT as it applies to both 
CVD and obesity. Completion of these experiments address a critical gap in our biological 
understanding of β-adrenergic receptors and their role in PVAT expansion, a critical area for 
therapeutic interventions. 
Based on the results from these growth assays, there are a few different paths of inquiry 
that can be taken. Firstly, it is important to test specific β-agonists and antagonists since 
Isoproterenol is a non-specific β-agonist. CL-316,243, Fenoterol, and Betaxolol may be used to 
determine the impact of specific β 1/2/3-agonist on PVAT expansion. Results from these 
different trials will provide a greater understanding of the role of β-receptors on AT growth and 
the therapy potential of each drug. Secondly, it is crucial to understand the different biological 
pathways underlying the process. Determining the relative levels of β-receptors and cAMP at 
different stages in the process by immunohistochemically analyzing tissue and cell media would 
quantify the process that is taking place after activation of the different PVAT. 
Recent research suggests that there are differences in VEGF receptors on the BAT and 
WAT which may help explain the results. BAT has a greater amount of VEGF receptors 
indicating BAT uses this type of growth stimulation while WAT does not (Hattori et al., 2007; 
Tonello et al., 1999). Provided the potential impact of VEGF presence on our results further 
investigations are warranted. 
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Once the most efficacious agonist is determined, the next critical step would be a 
collaboration with a cardiovascular surgeon to create a human clinical trial. Since rats and 
humans have different amounts of BAT and WAT, it would be important to test the effects of 
these drugs ex-vivo on human PVAT before proceeding to a clinical trial. This type of 
experimentation would be identical to the work that was done in vitro. In clinic, it would be 
possible to determine the effectiveness of the drug based on obesity progression in the patients. 
The trial would asses weight loss, heart health, and other typical obesity factors before and after 
administration of the drug. Based on the current results, a therapy may be more successful for 
patients with obesity and cardiovascular disease but clinical work is critical before conclusions 
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